Our findings that low FOXA1 expression is significantly associated with markers for worse outcome as well as poor survival appear to be in line with the TCGA data and findings in breast cancer, but in contrast to prostate cancer and one previous small, and potentially underpowered study of 109 endometrial carcinoma cases showing no significant prognostic impact of FOXA1 expression [24]. The gene discussed is FOXA1; the disease is prostate carcinoma.